A first-in-human, gene-silencing treatment for Alzheimer’s disease with Catherine Mummery
Genetic therapies are becoming a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. Since the groundbreaking results from IONIS-HTTRx (RG6042) for Huntington’s disease were announced, researchers across the globe have been working to translate gene-based approaches to other neurodegenerative diseases such as Alzheimer’s. In particular, the Neurogenetic Therapies Programme at University College London (UK) aims to facilitate drug discovery right from pre-clinical work in genetic therapies to first-in-man clinical trials. We recently spoke with Catherine Mummery, who is a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery (London, UK), at the Wolfson Closing Symposium (19 June 2019,...